Clinical outcomes of first 55 patients completing SmartFocus[®] electric field navigated rTMS therapy for treatment of major depressive disorder (MDD)

Nexstim NBT 2 system obtained FDA clearance for treatment of MDD in 2017 and was launched on the US market in May 2018. The NBT 2 system utilizes SmartFocus[®] technology that is a navigated transcranial magnetic stimulation (nTMS) technology with electric field navigation allowing patient-specific targeting of the TMS to the specific area of the brain.

After the launch in the US, clinical outcomes of Nexstim SmartFocus[®] rTMS treated patients have been collected in a registry. The registry holds only anonymized data provided by participating clinical sites using Nexstim's SmartFocus[®] technology.

Of the first 55 patients completing treatment at clinical sites in the United States, 22 (40%) had achieved clinical remission and 39 (71%) had obtained a clinical response at the end of treatment (Figure 1). Further, the patient reported experience of receiving treatment was generally very positive as reflected by a mean score of 8.7 on a scale of 0 to 10. ⁽¹⁾

The results are based on the patient reported outcome measures Beck's Depression Inventory (BDI, range of scores of test 0 - 63) and Patient Health Questionnaire -9 (PHQ-9, range of scores of test 0-27). Remission was defined as a PHQ9 score of less than 5 or BDI score of less than 10 while clinical response was defined as a PHQ9 score of less than 10 or BDI score of less than 19 at end of treatment.




Figure 1. Clinical remission and response rates at the end of SmartFocus[®] rTMS treatment in patients with major depressive disorder

1) Data on file at Nexstim Plc